Today, we are communicating a series of improvements that will further our ambition to innovate in the field of health technology assessment (HTA), adapt to changing regulatory and reimbursement environments, and improve the pathway that brings effective drugs to patients across Canada.
CADTH, Health Canada, and the Institut national d’excellence en santé et en services sociaux (INESSS) are seeking to advance the use of real-world evidence in regulatory and health technology assessment decision-making
A final guidance document published today provides important direction on reporting real-world evidence (RWE) studies in a way that maximizes transparency for regulatory and health technology assessment (HTA) decision-makers in Canada.
CADTH presents its top awards for career achievement to Dr. Brian O’Rourke and Dr. Kednapa Thavorn during the 2023 CADTH Symposium.
Ottawa, May 16, 2023 — Today, CADTH, Canada’s drug and health technology agency, announced the recipients of its 2023 Recognition Awards. These prizes honour individuals who are pushing the science of health technology assessment (HTA) forward, mentoring the next generation of leaders, and helping to grow Canada’s reputation for excellence in the field.
During a 1-year learning period, CADTH expanded its Scientific Advice program to include advice on real-world evidence (RWE), allowing applications after lockdown of protocols for pivotal trials. Based on the positive experience and considerable interest from industry, CADTH is formalizing this offering to enhance early engagement opportunities for pharmaceutical companies regarding RWE.
The position statement is a step toward greater transparency of unpublished data and a tangible outcome resulting from cooperation among global health technology assessment bodies
CADTH, Canada’s drug and health technology agency, in collaboration with the Institute for Clinical and Economic Review (ICER) in the US and the National Institute for Health and Care Excellence (NICE) in England, is announcing a position statement entitled Confidentiality of Clinical Evidence Informing Health Technology Assessment Decision-Making.
CADTH is inviting stakeholder feedback on a proposal to introduce time-limited reimbursement recommendations. These are recommendations that would be issued in favour of reimbursement in a manner that is time-limited and contingent upon a future reassessment of additional evidence that addresses the uncertainty with the comparative clinical benefit and cost-effectiveness for the drug or drug regimen under review.